质子抑制剂与肠道贝希特病风险之间的关联
Keita Murakami1, Junya Arai2, Sozaburo Ihara3
1K. Murakami, MD, S. Ihara, MD, PhD, M. Tsuboi, MD, PhD, K. Kurokawa, MD, PhD, N. Suzuki, MD, PhD, H. Kinoshita, MD, PhD, Y. Hayakawa, MD, PhD, M. Fujishiro, MD, PhD, Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo.
The Journal of rheumatology
|August 1, 2024
概括
质子抑制剂 (PPI) 的使用与已经被诊断为BD的患者患肠道Behcet病 (BD) 的风险更高有关. 这表明在给这些人开PPI时需要谨慎.
科学领域:
- 胃肠病学 胃肠病学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 贝塞特病 (BD) 是一种多系统性炎症性疾病.
- 肠道干扰是BD的严重并发症.
- 质子抑制剂 (PPI) 通常用于与酸有关的疾病.
研究的目的:
- 调查使用质子抑制剂 (PPI) 与肠道贝希特病 (BD) 发病率之间的关联.
- 评估使用PPI的BD患者患有肠道BD的风险.
主要方法:
- 东京大学医院的回顾性队列研究 (2005年4月 - 2023年11月).
- 包括194名BD患者.
- 使用Cox模型和Kaplan-Meier分析来评估危险比率和累积发病率.
- 二次分析检查了PPI持续时间和剂量反应关系.
主要成果:
- 在平均12年的随访期间,25.3%的BD患者患有肠道BD.
- PPI使用者显示肠道BD的发生率显著更高 (调整HR 2.48).
- 证实了PPI使用和肠道BD发病率之间的持续时间/剂量依赖关系.
- 在PPI使用者中,肠道BD的累积发病率明显增加 (日志排名P<0.001).
结论:
- 质子抑制剂 (PPI) 的使用显着与肠道贝切特病 (BD) 的发病率增加有关.
- 给患有BD的患者处方PPI需要谨慎,因为可能存在严重肠道并发症的潜在风险.
- 可能需要进一步的研究来阐明潜在的机制.
相关概念视频
01:30Peptic Ulcer Disease I: Introduction
162
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
162
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
364
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
364
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
362
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
362
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
558
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
558
01:17Gastritis-II: Pathophysiology
296
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
296
01:28Peptic Ulcer Disease II: Pathophysiology
344
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
344